Holen Sie sich die Stockscreener-App
16.96
1.01%
0.17
Vorhandelsmarkt:
17.01
0.05
+0.29%
Schlusskurs vom Vortag:
$16.79
Offen:
$16.73
24-Stunden-Volumen:
393.67K
Relative Volume:
0.52
Marktkapitalisierung:
$1.38B
Einnahmen:
$288.00K
Nettoeinkommen (Verlust:
$-228.06M
KGV:
-3.9906
EPS:
-4.25
Netto-Cashflow:
$-168.82M
1W Leistung:
+4.31%
1M Leistung:
+15.22%
6M Leistung:
-7.57%
1J Leistung:
+13.22%
1-Tages-Spanne:
$16.69
$17.22
1-Wochen-Bereich:
$16.42
$17.41
52-Wochen-Spanne:
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Firmenname
Viridian Therapeutics Inc
Sektor
Branche
Telefon
617.272.4600
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie VRDN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
16.96 | 1.33B | 288.00K | -228.06M | -168.82M | -4.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Eingeleitet | TD Cowen | Buy |
| 2024-09-11 | Bestätigt | Needham | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-05-09 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Eingeleitet | BTIG Research | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-05-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-04-17 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2022-12-19 | Eingeleitet | Cowen | Outperform |
| 2022-12-19 | Eingeleitet | Needham | Buy |
| 2022-12-16 | Eingeleitet | Credit Suisse | Outperform |
| 2022-12-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-23 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-18 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Is Viridian Therapeutics Inc. a good long term investmentOutstanding risk-reward balance - Autocar Professional
What drives Viridian Therapeutics Inc. stock priceFree Investment Community - jammulinksnews.com
What analysts say about Viridian Therapeutics Inc. stockOutperformance with explosive growth - jammulinksnews.com
Why Viridian Therapeutics Inc. stock attracts strong analyst attentionBreakout Level Watch - Newser
Viridian Therapeutics Inc. Stock Analysis and ForecastSuperior returns - Autocar Professional
Teacher Retirement System of Texas Decreases Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
(VRDN) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Principal Financial Group Inc. Acquires 30,392 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics’ Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial - MSN
13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey
What makes Viridian Therapeutics Inc. stock price move sharplyFast Moving Stock Alerts - Newser
How Viridian Therapeutics Inc. stock performs during market volatilitySafety First Trading Signals - Newser
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $38 - 富途牛牛
Amalgamated Bank Has $34,000 Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Evercore ISI Lowers Viridian Therapeutics Price Target to $38 - AInvest
Viridian Therapeutics Sees Relative Strength Rating Improve To 79 - MSN
(VRDN) Investment Analysis - news.stocktradersdaily.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Viridian Therapeutics: Fueling R&D Breakthroughs Through Strategic Equity Incentives - AInvest
Is Viridian Therapeutics (NASDAQ:VRDN) A Risky Investment? - simplywall.st
(VRDN) On The My Stocks Page - news.stocktradersdaily.com
When (VRDN) Moves Investors should Listen - news.stocktradersdaily.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $37.56 Average Target Price from Analysts - Defense World
Viridian Therapeutics’ SWOT analysis: promising TED treatment stock faces pivotal year - Investing.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by California State Teachers Retirement System - Defense World
Viridian Therapeutics: The Song Remains The Same (NASDAQ:VRDN) - Seeking Alpha
Transcript : Viridian Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.22 Million Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Where are the Opportunities in (VRDN) - news.stocktradersdaily.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VRDN Stock News - GuruFocus
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics shares fall as Q1 loss narrows, revenue beats By Investing.com - Investing.com Nigeria
Finanzdaten der Viridian Therapeutics Inc-Aktie (VRDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):